Teplizumab: What You Need to Know About Canada's First Disease-Modifying T1D Therapy

On May 5, 2025, Health Canada approved teplizumab (marketed as Tzield), marking a watershed moment for the Type 1 diabetes community. This is the first disease-modifying therapy approved in Canada—a medicine designed to address the autoimmune process that destroys insulin-producing beta cells in the pancreas.

Teplizumab is a monoclonal antibody that works by modulating the immune system's attack on the pancreas. Clinical evidence shows it can delay the onset of symptomatic Type 1 diabetes in people ages 8 and older who have detectable autoimmune markers and early blood sugar changes—a stage called Stage 2 T1D. This represents a meaningful shift from only managing diabetes after diagnosis to potentially preventing it before it develops.

Type 1 diabetes progresses through three distinct stages. Stage 1 involves autoimmune activity against beta cells but normal blood sugar. Stage 2 includes autoimmune markers plus mild blood sugar abnormalities. Stage 3 is symptomatic Type 1 diabetes with elevated blood sugar—the clinical diagnosis most people recognize.

Teplizumab was approved to delay progression at Stage 2, before full diabetes develops. This timing is crucial: the therapy works best when started early, in people identified through screening before they experience diabetes symptoms. International clinical guidelines now emphasize the importance of identifying and monitoring people in these early stages.

Despite Health Canada approval, Canadian patients face significant access barriers. In August 2025, Canada's Drug Agency (CDA) issued a draft recommendation against reimbursement. In October 2025, Quebec's health institute (INESSS) decided not to cover the drug. In January 2026, the CDA finalized its decision: no reimbursement through public drug plans.

Patient advocates, healthcare providers, and the drug sponsor submitted feedback urging reconsideration, but the decisions stood. These recommendations are non-binding, meaning provincial drug plans are unlikely to cover Tzield. However, private insurance—such as employer benefits plans—may still choose to cover the therapy.

Breakthrough T1D Canada and Diabetes Canada continue advocating for equitable and cost-effective access to teplizumab for Canadian patients with early-stage disease.

Teplizumab's approval has prompted the international diabetes community to reassess how we think about Type 1 diabetes. The International Society for Pediatric and Adolescent Diabetes (ISPAD) updated its clinical guidelines in 2024 to include new recommendations on screening for T1D risk and monitoring people in early stages.

Beyond teplizumab, researchers continue exploring other immunomodulatory agents and cell-based therapies at various disease stages. Some target the prevention of beta-cell destruction, others aim to preserve remaining beta-cell function, and emerging approaches include stem cell therapies. The field is moving toward a more nuanced understanding of T1D risk, with recognition that progression is not always linear and that better prediction tools are needed.

Experts also emphasize that the current disease staging system has limits. A single framework cannot capture all the factors that influence who will develop Type 1 diabetes and how quickly. Future advances may include more personalized risk calculators incorporating genetics, autoantibodies, metabolic markers, and immune data—enabling more precise identification of who could benefit from early intervention.

Origin: breakthrought1d.ca (News report). Evidence: News report, corroborated with 3 indexed studies. Type1Cure is an information and intelligence hub, not a medical advice service. This article summarizes published research and does not provide diagnosis, treatment, or personal medical guidance. Always talk to your own care team before changing anything about your Type 1 diabetes management.